Article info
PDFExtended essay
From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
- Correspondence to Dr Nancy S Jecker, Department of Bioethics & Humanities, University of Washington School of Medicine, 1959 Pacific Street, Box 357120, Seattle, WA 98195-7120, USA; nsjecker{at}uw.edu
Citation
From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
Publication history
- Received August 8, 2016
- Revised January 25, 2017
- Accepted February 13, 2017
- First published April 13, 2017.
Online issue publication
May 26, 2017
Article Versions
- Previous version (13 April 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- What is CAR T-cell therapy?
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Cardiotoxicities of novel cancer immunotherapies
- CAR-T treatment for hematological malignancies
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know